GOSS

Gossamer Bio, Inc.

0.17 USD

Last updated Sep 4, 19:45 UTC

Yesterday HIGH

$0.18

Yesterday LOW

$0.16

52w HIGH

$3.86

52w LOW

$0.11

EPS

-0.08

PE

-2.18

Next Earnings

Nov 4, 2026

Overview News Insider Transactions Government Trades Fundamentals

Gossamer Bio, Inc. stock is down -2.94% since 30 days ago. The next earnings date is Nov 4, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 7 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Mon Jul 27, 2026

Gossamer Bio Advances Seralutinib Toward NDA In September 2026, Reacquires Global Rights To Seralutinib From Chiesi

– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH –– Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential
Benzinga Newsdesk

Thu Jun 25, 2026

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $2

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $5 to $2.
Benzinga Newsdesk

Wed Jun 17, 2026

Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And Equity

Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and
Benzinga Newsdesk

Tue May 26, 2026

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $5 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $5 price target.
Benzinga Insights

Mon May 18, 2026

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights

Mon May 18, 2026

Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga Insights

Mon May 18, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Newsdesk

Mon May 18, 2026

Gossamer Bio Launches Exchange Offer For $72M New 7.5% Notes, Up To 317.6M Shares/Prefunded Warrants, Plus Early Tender Purchase Warrants

Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary
Benzinga Newsdesk

Mon May 18, 2026

Gossamer Bio Q1 EPS $(0.20) Misses $(0.13) Estimate, Sales $16.955M Beat $4.475M Estimate

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.13) by 53.85 percent. This is a 25 percent decrease over losses of $(0.16) per share from the
Benzinga Insights

Fri Apr 24, 2026

12 Health Care Stocks Moving In Friday's After-Market Session

Piper Sandler

Fri Aug 14, 18:35

buy

confirm

Advanced Data Unlock

Waage Christian, EVP

Mon Aug 24, 2026

GOSS Recent Insider Trades and Stock Chart

2,900,026 shares awarded
Caryn Peterson, Chief Development Officer

Mon Aug 24, 2026

GOSS Recent Insider Trades and Stock Chart

5,800,051 shares awarded
Paul Robert Smith JR, Chief Commercial Officer

Mon Aug 24, 2026

GOSS Recent Insider Trades and Stock Chart

5,800,051 shares awarded
Bryan Giraudo, COO/CFO

Mon Aug 24, 2026

GOSS Recent Insider Trades and Stock Chart

5,800,051 shares awarded
Bryan Giraudo, COO/CFO

Mon Aug 24, 2026

GOSS Recent Insider Trades and Stock Chart

25 shares awarded
Faheem Hasnain, President & CEO

Mon Aug 24, 2026

GOSS Recent Insider Trades and Stock Chart

5,800,051 shares awarded
Faheem Hasnain, President & CEO

Mon Aug 24, 2026

GOSS Recent Insider Trades and Stock Chart

166 shares awarded